摘要
目的研究该中心无偿献血传染标志物筛查不合格结果,为科学合理制订血液筛查策略,评估血液筛查试剂的检测效率提供依据。方法统计该中心2014年7月至2015年6月无偿献血传染标志物筛查不合格结果及检测试剂分布。结果该中心2014年7月至2015年6月共检测标本120 756例,筛查出不合格标本共2 854例,其中ELISA阳性/病毒核酸检测阳性(ELISA^+/NAT^+)标本768例,ELISA^+/NAT-标本1 748例,ELISA^-/NAT^+标本338例(111例NAT鉴别结果为HBV);抗-TP、HBsAg、抗-HIV、抗-HCV不合格标本分别为895、1 012、276和444例,ELISA双试剂不合格率依次为78.6%、77.3%、30.8%、26.1%。NAT检测不合格以HBV检出为主,仅HBsAg有ELISA单试剂阳性献血者,NAT联检阳性且鉴别结果为HBV的。结论在不违反相关法律法规及操作规范下,合理选择一遍ELISA加一遍NAT的检测策略切实可行。
Objective To investigate the unquanlified screening results of blood donors＇ infectious markers in this center,develop a scientific blood screening policy and provide a basis for assessing the efficiency of blood screening reagent. Methods unquanlified screening results of blood donors＇ infectious markers in this center were analyzed from July 2014 to June 2015,and the distribution of detection reagents were also detected. Results 120 756 samples were detected in Chongqing blood center; among 2 854 cases of unquanlified samples,there were 768 cases of ELISA^＋/NAT^＋ ,38 cases of NAT^＋/ELISA^- 3 （111 cases NAT were i- dentified as HBV） ; unqualified specimens of anti-TP, HBsAg, anti-HIV, anti-HCV were 895,1 012,276 and 444 cases respectively; Double ELISA reagent unqualified rate were 78.6%, 77.3%,30.8%, 26.1% respectively. The main unqualified results of NAT were HBV,the blood donors that were reactive in only HBsAg single reagent of ELISA also reactive for HBV in differential NAT. Conclusion On the condition that comply with laws and operations specification, the blood screening strategy of selecting once ELISA and once NAT rationally is feasible.
出处
《重庆医学》
CAS
北大核心
2016年第2期236-237,240,共3页
Chongqing medicine
关键词
供血者
传染标志物
合格鉴定
blood donors
infectious markers
eligibility determination
